EUVIMED · CrossrefZeitschrift
SKIN The Journal of Cutaneous Medicine
ISSN 2574-1624 · Dermsquared
Neueste Artikel
Cutaneous Myiasis in an Immunocompromised Patient: Climate Change as an Emerging Driver
Platelet-Rich Plasma for Cutaneous Wound Healing: Clinical Outcomes Across Wound Etiologies
Effects of Glucagon-Like Peptide-1 (GLP-1)–Based Medications on Icotrokinra Efficacy, Safety, and Pharmacokinetics: Pooled Results Across ICONIC Phase 3 Studies
Comparative efficacy of upadacitinib and nemolizumab in combination with background topical therapy in adults and adolescents with moderate-to-severe atopic dermatitis: a placebo-anchored matching-adjusted indirect comparison
Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes
Retrospective Observation of Liver Function Tests in Biologic-Treated Patients with Psoriasis, Psoriatic Arthritis, and/or Hidradenitis Suppurativa
Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis
Bimekizumab Leads to Sustained Flare-Free Status in Moderate to Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT
Bimekizumab Improves Draining Tunnel Outcomes in Patients with Moderate to Severe HS Regardless of Prior Biologic Use: 3-Year Data from BE HEARD EXT
Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction
Real-world use of subcutaneous spesolimab for ongoing disease control in generalized pustular psoriasis: A report of two patient cases
Two Cases of Generalized Ribociclib-Induced Vitiligo
Clinical Tolerability and Quality of Life Assessment of a Novel Panthenol and Bisabolol-enhanced Cream and Lotion in Adults with Mild to Moderate Dermatologic Conditions
Real‑World Insurance Access to FDA-Approved Ruxolitinib Cream in Vitiligo
Reticulated ulcers on the bilateral legs
Envudeucitinib Provides Rapid and Sustained Itch Relief, Including Complete Itch Resolution, in Patients with Moderate-to-Severe Plaque Psoriasis: 24 Week Results from the Phase 3 ONWARD 1 and ONWARD2 Trials
Efficacy of Risankizumab Compared to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis Affecting High-Impact Areas: An Integrated Post hoc Analysis of the Phase 3 UltIMMa-1 and UltIMMa-2 Trials
Diet Quality and Non Melanoma Skin Cancer Among U.S. Adults: A Cross-Sectional Analysis of NHANES 1999-2026
Topical Corticosteroid-Refractory Chronic Hand Eczema Successfully Treated with Delgocitinib: A Case Report
Impact of GLP-1 Receptor Agonist Therapy on Outcomes in Hidradenitis Suppurativa: A TriNetX Database Study
Sex-specific and age-adjusted prevalence of hidradenitis suppurativa: Results from Komodo US claims data suggest sex parity of HS symptoms
Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data
Daxdilimab in Moderate-to-Severe Discoid Lupus Erythematosus: Efficacy and Safety Results From a Phase 2, Randomized, Placebo-Controlled Trial
Real world analysis of paid claims database reveals that disseminated superficial actinic porokeratosis (DSAP) is large orphan disease
Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment
Empowering psoriasis shared decision-making (SDM) with digital tools
Impact of Dupilumab on Bone Mineralization Biomarker and Growth Metrics in Children Aged 2 to Under 12 Years With Moderate-to-Severe Atopic Dermatitis
Racial differences in post-transplant skin cancer among heart transplant recipients: a single-center matched cohort study
Sustained Improvement in Atopic Dermatitis Disease Control and Treatment Satisfaction With Dupilumab in Clinical Practice: 7-Year Follow-up Results From the RELIEVE-AD Study
Real-world dosing of adalimumab and secukinumab in hidradenitis suppurativa: Updated biologic treatment pattern analysis
EUVIMED